eXoZymes, Inc. (EXOZ NASDAQ) stock market data APIs
$10.2004
-0.11(-1.1%)
as of February 13, 2026
Try our APIs with
free plan!
eXoZymes, Inc. Financial Data Overview
Price chart is built with
Anychart
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Prev. Close
10.2004
Open
10.0893
High
10.3787
Low
10.0647
52 wk Range
8.86-21.99
Market Cap
85 872 K
Shares Outstanding
8 400 K
Revenue
-700
EPS
-0.27
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with eXoZymes, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get eXoZymes, Inc. data using free add-ons & libraries
Get eXoZymes, Inc. Fundamental Data
eXoZymes, Inc. Fundamental data includes:
- Net Revenue: -700
- EBITDA: -8 722 368
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
eXoZymes, Inc. News
New
Earnings call transcript: eXoZymes' Q2 2025 focuses on innovation and partnerships
eXoZymes Inc reported its Q2 2025 financial performance, revealing a net loss of $2.36 million and year-to-date losses of $4.22 million. The company maintains a strong cash position with $6.99 million...
InvestingPro Fair Value model correctly predicts eXoZymes' 40% price drop
In a compelling demonstration of analytical precision, Investing.com’s Fair Value model successfully identified significant overvaluation in eXoZymes Inc. (NASDAQ:EXOZ) shares in December 2024. The ...
Bringing clarity and precision to the cell-free space by introducing exozymes
Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes’ to bring clarity to the ra...
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceutical...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
